表紙:末梢神経鞘腫瘍 (神経線維肉腫) :開発中の薬剤
市場調査レポート
商品コード
362363

末梢神経鞘腫瘍 (神経線維肉腫) :開発中の薬剤

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 567 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
末梢神経鞘腫瘍 (神経線維肉腫) :開発中の薬剤
出版日: 2021年12月30日
発行: Global Markets Direct
ページ情報: 英文 567 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、末梢神経鞘腫瘍 (神経線維肉腫) 治療薬の開発状況について調査しており、パイプライン製品の概要、治験段階別の製品概要、主要企業および薬剤のプロファイル、パイプライン製品の最新動向、および最新ニュース/プレスリリースなどを提供しています。

イントロダクション

  • 調査範囲

末梢神経鞘腫瘍 (神経線維肉腫) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

末梢神経鞘腫瘍 (神経線維肉腫):企業で開発中の治療薬

末梢神経鞘腫瘍 (神経線維肉腫):大学/機関で研究中の治療薬

末梢神経鞘腫瘍 (神経線維肉腫):パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

末梢神経鞘腫瘍 (神経線維肉腫):企業で開発中の製品

末梢神経鞘腫瘍 (神経線維肉腫):大学/機関で研究中の製品

末梢神経鞘腫瘍 (神経線維肉腫)の治療薬開発に従事している企業

  • Bexion Pharmaceuticals, LLC.
  • EpiZyme, Inc.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Plexxikon Inc.
  • Synta Pharmaceuticals Corp.
  • Vyriad

末梢神経鞘腫瘍 (神経線維肉腫):治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

末梢神経鞘腫瘍 (神経線維肉腫):最近のパイプライン動向

末梢神経鞘腫瘍 (神経線維肉腫):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Target, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by 3SBio Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Advenchen Laboratories LLC, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Aldeyra Therapeutics Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Apexian Pharmaceuticals Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Ascentage Pharma Group International, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by AstraZeneca Plc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by BeiGene Ltd, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Bristol-Myers Squibb Co, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Calithera Biosciences Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Epizyme Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Karyopharm Therapeutics Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Merck & Co Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Mirati Therapeutics Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Novartis AG, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Oncomatryx Biopharma SL, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Open Therapeutics LLC, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Otsuka Pharmaceutical Co Ltd, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pfizer Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pharma Mar SA, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Plexxikon Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Resverlogix Corp, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Sino Biopharmaceutical Ltd, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Sorrento Therapeutics Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Vyriad Inc, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects, 2021
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC13210IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drugs In Development, 2021, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline landscape.

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 18, 4, 1, 4 and 1 respectively.

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drug Profiles
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Discontinued Products
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer